Difference between revisions of "Ruxolitinib (Jakafi)"
Jump to navigation
Jump to search
(updated content) |
|||
| Line 1: | Line 1: | ||
| − | |||
| − | |||
==General information== | ==General information== | ||
| − | Class/mechanism: Kinase inhibitor of Janus Associated Kinases (JAKs) JAK1 and JAK2. Modulates gene expression by interfering with the JAK signaling pathway, which involves recruitment, activation, and localization of STATs (signal transducers and activators of transcription) to cytokine receptors and the nucleus.<ref name="insert">[http://www.incyte.com/products/uspi_jakafi.pdf Ruxolitinib (Jakafi) package insert]</ref><ref>[ | + | Class/mechanism: Kinase inhibitor of Janus Associated Kinases (JAKs) JAK1 and JAK2. Modulates gene expression by interfering with the JAK signaling pathway, which involves recruitment, activation, and localization of STATs (signal transducers and activators of transcription) to cytokine receptors and the nucleus.<ref name="insert">[http://www.incyte.com/products/uspi_jakafi.pdf Ruxolitinib (Jakafi) package insert]</ref><ref>[[Media:Ruxolitinib.pdf | Ruxolitinib (Jakafi) package insert (locally hosted backup)]]</ref> |
<br>Route: PO | <br>Route: PO | ||
<br>Extravasation: n/a | <br>Extravasation: n/a | ||
| − | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref><ref>[http://www.jakafi.com/ Jakafi manufacturer's website]</ref> |
==Diseases for which it is used== | ==Diseases for which it is used== | ||
| Line 13: | Line 11: | ||
==Patient drug information== | ==Patient drug information== | ||
| − | *[http://www.incyte.com/products/uspi_jakafi.pdf | + | *Patient information may be found in the [http://www.incyte.com/products/uspi_jakafi.pdf Ruxolitinib (Jakafi) package insert]<ref name="insert"></ref> |
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | * 11/16/2011: Initial FDA approval for treatment of patients with intermediate or high-risk [[Myelofibrosis | myelofibrosis]], including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis. | + | * 11/16/2011: [http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm280155.htm Initial FDA approval] for treatment of patients with intermediate or high-risk [[Myelofibrosis | myelofibrosis]], including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis. |
| − | * 12/4/2014: FDA indication expanded "for the treatment of patients with [[Polycythemia vera|polycythemia vera (PV)]] who have had an inadequate response to or are intolerant of [[Hydroxyurea (Hydrea)|hydroxyurea (HU)]]." | + | * 12/4/2014: [http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm425677.htm FDA indication expanded] "for the treatment of patients with [[Polycythemia vera|polycythemia vera (PV)]] who have had an inadequate response to or are intolerant of [[Hydroxyurea (Hydrea)|hydroxyurea (HU)]]." |
| + | |||
| + | ==Also known as== | ||
| + | INCB018424. | ||
==References== | ==References== | ||
Revision as of 07:06, 5 December 2014
General information
Class/mechanism: Kinase inhibitor of Janus Associated Kinases (JAKs) JAK1 and JAK2. Modulates gene expression by interfering with the JAK signaling pathway, which involves recruitment, activation, and localization of STATs (signal transducers and activators of transcription) to cytokine receptors and the nucleus.[1][2]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1][3]
Diseases for which it is used
Patient drug information
- Patient information may be found in the Ruxolitinib (Jakafi) package insert[1]
History of changes in FDA indication
- 11/16/2011: Initial FDA approval for treatment of patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis.
- 12/4/2014: FDA indication expanded "for the treatment of patients with polycythemia vera (PV) who have had an inadequate response to or are intolerant of hydroxyurea (HU)."
Also known as
INCB018424.